Updated results from the CHOPIN Phase 1b Trial in seven patients with advanced uveal melanoma treated with CHEMOSAT and ipilimumab plus nivolumab show a Median PFS of 29.1 months
January 17, 2023
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
Updated results from the CHOPIN Phase 1b Trial in seven patients with advanced uveal melanoma treated with CHEMOSAT and ipilimumab plus nivolumab show a Median PFS of 29.1 months